197 related articles for article (PubMed ID: 22046416)
21. Hippocampal low-frequency stimulation increased SV2A expression and inhibited the seizure degree in pharmacoresistant amygdala-kindling epileptic rats.
Wang L; Shi J; Wu G; Zhou F; Hong Z
Epilepsy Res; 2014 Nov; 108(9):1483-91. PubMed ID: 25205164
[TBL] [Abstract][Full Text] [Related]
22. Genetics of reflex seizures and epilepsies in humans and animals.
Italiano D; Striano P; Russo E; Leo A; Spina E; Zara F; Striano S; Gambardella A; Labate A; Gasparini S; Lamberti M; De Sarro G; Aguglia U; Ferlazzo E
Epilepsy Res; 2016 Mar; 121():47-54. PubMed ID: 26875109
[TBL] [Abstract][Full Text] [Related]
23. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
Gillard M; Chatelain P; Fuks B
Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
[TBL] [Abstract][Full Text] [Related]
24. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.
Tokudome K; Okumura T; Shimizu S; Mashimo T; Takizawa A; Serikawa T; Terada R; Ishihara S; Kunisawa N; Sasa M; Ohno Y
Sci Rep; 2016 Jun; 6():27420. PubMed ID: 27265781
[TBL] [Abstract][Full Text] [Related]
25. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD
Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248
[TBL] [Abstract][Full Text] [Related]
26. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
[TBL] [Abstract][Full Text] [Related]
27. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
[TBL] [Abstract][Full Text] [Related]
28. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
[TBL] [Abstract][Full Text] [Related]
29. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Sands ZA; Vandenplas C; Gillard M
Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
[TBL] [Abstract][Full Text] [Related]
30. Low distribution of synaptic vesicle protein 2A and synaptotagimin-1 in the cerebral cortex and hippocampus of spontaneously epileptic rats exhibiting both tonic convulsion and absence seizure.
Hanaya R; Hosoyama H; Sugata S; Tokudome M; Hirano H; Tokimura H; Kurisu K; Serikawa T; Sasa M; Arita K
Neuroscience; 2012 Sep; 221():12-20. PubMed ID: 22766234
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Gillard M
Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
[TBL] [Abstract][Full Text] [Related]
32. Synaptic vesicle protein 2A mitigates parthanatos via apoptosis-inducing factor in a rat model of pharmacoresistant epilepsy.
Li C; Wang Z; Ren M; Ren S; Wu G; Wang L
CNS Neurosci Ther; 2024 May; 30(5):e14778. PubMed ID: 38801174
[TBL] [Abstract][Full Text] [Related]
33. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
[TBL] [Abstract][Full Text] [Related]
34. Brain chimeras in birds: application to the study of a genetic form of reflex epilepsy.
Batini C; Teillet MA; Naquet R; Le Douarin NM
Trends Neurosci; 1996 Jun; 19(6):246-52. PubMed ID: 8761961
[TBL] [Abstract][Full Text] [Related]
35. Behavioural phenotyping reveals anxiety-like features of SV2A deficient mice.
Lamberty Y; Detrait E; Leclercq K; Michel A; De Ryck M
Behav Brain Res; 2009 Mar; 198(2):329-33. PubMed ID: 19041904
[TBL] [Abstract][Full Text] [Related]
36. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
[TBL] [Abstract][Full Text] [Related]
37. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.
Contreras-García IJ; Gómez-Lira G; Phillips-Farfán BV; Pichardo-Macías LA; García-Cruz ME; Chávez-Pacheco JL; Mendoza-Torreblanca JG
Brain Sci; 2021 Apr; 11(5):. PubMed ID: 33922424
[TBL] [Abstract][Full Text] [Related]
38. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release.
Janz R; Goda Y; Geppert M; Missler M; Südhof TC
Neuron; 1999 Dec; 24(4):1003-16. PubMed ID: 10624962
[TBL] [Abstract][Full Text] [Related]
39. An avian model of genetic reflex epilepsy.
Batini C; Teillet MA; Naquet R
Arch Ital Biol; 2004 May; 142(3):297-312. PubMed ID: 15260383
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
